MK-2060, Placebo to MK-2060
MK-2060-007
Phase 2 small_molecule active
Quick answer
MK-2060, Placebo to MK-2060 for Prevention of arteriovenous graft thrombosis is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Prevention of arteriovenous graft thrombosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active